Compare Abeona Therapeutics Inc (ABEO) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Nasdaq Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Nasdaq Inc trades at $85.07 (market cap $48.88B). The key difference: Nasdaq Inc is far larger — about 130.9× Abeona Therapeutics Inc's market cap, and Nasdaq Inc pays a 1.3% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NDAQ | |
|---|---|---|
Market Cap | $373.32M | $48.88B |
Sector | Health | Financials |
52-Week High | $7.23 | $100.98 |
52-Week Low | $4.17 | $76.85 |
Enterprise Value | $228.22M | $55.94B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Nasdaq (NDAQ) trades at $86.43, up 2.09% with strong fundamental performance including 2025 revenue of $8.26B and net income of $1.79B. The stock shows bullish technical signals with support at $83 and resistance at $86, while maintaining consistent earnings beats in recent quarters. Recent news highlights Nasdaq's record trading volumes and strategic expansions.
Outlook remains positive with analyst consensus target of $103 (19% upside), though risks include market volatility sensitivity and competitive pressures. The company's dominant exchange position and growing IPO pipeline provide solid growth foundation for investors seeking financial services exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
